BioNJ's Patient Advocacy Summit

Celgene Corporation, 181 Passaic Ave, Summit, NJ

December 13, 2018

Register now!

Inspiring Women in STEM Conference

Sanofi , Bridgewater, NJ

December 7, 2018

Register now!

February 7, 2019

Save the date!

They didn't need the 39 th Edison Patent Awards, created and run by  The Research & Development Council of New Jersey, to know some of the most innovative patents and products are still being developed in New Jersey by some of the world's top companies. They live it every day. " "These ideas and breakthroughs are not all happening in Boston and California and elsewhere," said Tony Cicatiello, the President of the R&D Council. "And the reason is simple: Fundamentally, we have a base of people with talent and knowledge and they like to be able to stay close and collaborate...Science is getting so sophisticated that you need to have the collaboration. We have a lot of good scientists in this State and they want to stay here."

While understanding the impact of  myelodysplastic syndromes (MDS) on the lives of people diagnosed with these blood cancers can help inform their care, assessments of quality of life in MDS have been, for the most part, lacking.  But a recent survey commissioned by the  MDS Foundation, Inc.  is helping to fill that gap, to shed some much-needed light on the experience of patients and their caregivers. According to the results, many people with MDS surveyed said that fatigue had a significant impact on their daily lives.

More than 150,000 children and adults in the United States live with eosinophilic esophagitis, a relatively new disease that was only first recognized in the 1990s. There are currently no FDA-approved pharmaceuticals to treat EoE. Symptoms may be managed with elimination diets and other methods. Julie is sharing their story to raise awareness of the disease, with the hope that more can be done to improve their daily struggle.

 

Hampton-based BioNJ Member   Celldex Therapeutics, Inc.  presented interim data from the Phase 1 dose-escalation study of CDX-1140, a fully human agonist anti-CD40 antibody. "CDX-1140 was specifically designed to balance systemic dosing and safety, which has proven elusive for CD40-targeted activating therapeutics," said Tibor Keler , Ph.D., Executive Vice President and Chief Scientific Officer of  Celldex Therapeutics . "We have completed four of the potential eight monotherapy dose levels and, to date, CDX-1140 has been well tolerated.

 

Hampton-based BioNJ Member   Celldex Therapeutics, Inc.  presented data from the company's MerTK antibody program at the  Society for Immunotherapy of Cancer's  ( SITC ) 33rd Annual Meeting. "Through our significant discovery effort, we have identified two unique antibodies that modulate this pathway resulting in profound levels of cytokine and chemokine production, and importantly we have developed preclinical models that support the premise that antibody modulation of MerTK can lead to antitumor responses," said Tibor Keler , Ph.D., Executive Vice President and Chief Scientific Officer of  Celldex Therapeutics .

 

Cranbury-based BioNJ Member   Oncobiologics, Inc.  announced that it has begun dosing patients in its first clinical trial for ONS-5010, a proprietary ophthalmic bevacizumab product candidate, in patients with wet age related macular degeneration (wet AMD). This first clinical study for ONS-5010, the company's lead product candidate, is being conducted outside of  the United States  and is designed to serve as the first of two adequate and well controlled studies for wet AMD. 

 

Cranbury-based BioNJ Member   Palatin Technologies, Inc. announced Phase 1, first-in-human results of a single and multiple ascending-dose study of PL-8177, a patented melanocortin receptor 1 agonist with the potential application of treating ulcerative colitis and other inflammatory diseases. The data of subcutaneous administration of PL-8177 demonstrated favorable pharmacokinetics and pharmacodynamic properties and no safety or tolerability concerns were reported.

 

Bedminster-based BioNJ Member   Amarin Corporation  plc announced the primary results from the Vascepa® (icosapent ethyl) cardiovascular (CV) outcomes trial, REDUCE-IT™.  REDUCE-IT primary results confirmed 25% relative risk reduction (RRR) for the topline primary endpoint result with multiple robust demonstrations of efficacy, including 20% reduction in cardiovascular death. REDUCE-IT was a global study of 8,179 statin-treated adults with elevated CV risk. 

 

BioNJ Member   Jazz Pharmaceuticals plc, with offices in  Ewing, announced the submission of a Marketing Authorization Application (MAA) to the  European Medicines Agency  for solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor, as a treatment to improve wakefulness and reduce excessive daytime sleepiness ( EDS ) in adult patients with narcolepsy (with or without cataplexy) or obstructive sleep apnea (OSA). 

 

BioNJ Member   Jazz Pharmaceuticals plc, with offices in  Ewing,  announced that the  National Institute for Health and Care Excellence(NICE) has published a Final Appraisal Determination (FAD) recommending Vyxeo® 44 mg/100 mg powder for concentrate for solution for infusion for routine use on the National Health Service (NHS) in England and Wales for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) 1 - -   two types of secondary AML.

 

East Hanover-based BioNJ Member   Novartis announced results of the landmark PIONEER-HF trial showing that in-hospital initiation of Entresto tablets provided superior benefit compared to enalapril-a heart failure medication commonly used-in patients with HFrEF who had been stabilized following admission for an acute decompensation heart failure (ADHF) event. Patients on Entresto in PIONEER-HF had a 29% greater reduction in time-averaged N-terminal pro-B-type natriuretic peptide (NT-proBNP) at weeks 4 and 8 (the primary endpoint) compared to enalapril patients (95% CI: 0.63, 0.81; P<0.0001).

 

Berkeley Heights-based BioNJ Member  Cyclacel Pharmaceuticals Inc.  and The University of Texas  MD Anderson Cancer Center  have entered into a three-year agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, several advanced leukemias. According to Cyclacel, MD Anderson will conduct four clinical studies with a total projected enrollment of up to 170 patients, which will investigate CYC065, CYC140 and sapacitabine either as single agents or in combination with approved drugs.

 

Plainsboro-based BioNJ Member   Novo Nordisk A/S and Embark Biotech ApS a nnounced that they have entered into a research collaboration focusing on the discovery of novel treatments for obesity and its associated metabolic pathologies through mechanisms that increase energy expenditure. The research platform of Embark Biotech, a recent spin-out from Center for Basic Metabolic Research at University of Copenhagen, builds on novel and unique insights into receptors that stimulate energy expenditure without triggering the sympathetic nervous system (the 'fight-or-flight' response).  

 

Pennington-based BioNJ Member  OncoSec Medical Incorporated announced that the first patient has been treated in KEYNOTE-890, a Phase 2 clinical trial for the treatment of late-stage triple negative breast cancer (TNBC) with TAVO™ (intratumoral plasma encoded IL-12, or tavokinogene telseplasmid, plus electroporation) in combination with Merck's KEYTRUDA® (pembrolizumab). KEYNOTE-890 is designed as a multicenter Phase 2 open-label trial focusing on patients with a histologically confirmed diagnosis of inoperable locally advanced or metastatic TNBC and at least 1 prior line of approved systemic chemotherapy or immunotherapy.  

 

Pennington-based BioNJ Member  OncoSec Medical Incorporated announced that TAVO™ will be featured in two poster sessions during the 2018 San Antonio Breast Cancer Symposium (SABCS). "We are encouraged with the preliminary clinical observations we are seeing thus far, both in a monotherapy setting and in combination with checkpoint inhibitors," said Daniel J. O'Connor, President and Chief Executive Officer of OncoSec. "Based on this, we are excited to continue on the path toward developing novel treatment options for this large unmet medical need."

 

Morris Plains-based BioNJ Member  Immunomedics, Inc. announced its current clinical collaboration with AstraZeneca and MedImmune for the development of Imfinzi® (durvalumab) and sacituzumab govitecan combination therapy has been broadened to include second-line metastatic non-small cell lung cancer (NSCLC).  "Sacituzumab govitecan has shown very encouraging single-agent activity in NSCLC patients who have failed multiple lines of therapy. The combination study with durvalumab, together with our internal efforts to further develop sacituzumab govitecan monotherapy, will help us define the best registration strategies in NSCLC within accelerated timelines," said Dr. Robert Iannone, Head of Research & Development and Chief Medical Officer of Immunomedics.

 

The United States Food and Drug Administration (FDA) has accepted a Biologics License Application for Bridgewater-based BioNJ Member Sanofi Pasteur's dengue vaccine.  The dengue vaccine candidate has been granted priority review by the FDA as it would represent the first and only medical prevention tool against dengue, including severe dengue, which is considered an unmet medical need. The FDA set a Prescription Drug User Fee Act action date of  May 1, 2019 .

 

The U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Bridgewater-based BioNJ Member Sanofi's Dupixent®(dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with moderate-to-severe atopic dermatitis.

 

Bridgewater-based B ioNJ Member Sanofi's Praluent® (alirocumab) Injection was associated with fewer deaths from any cause among patients who had previously experienced a heart attack or unstable angina (known as acute coronary syndrome, or ACS), and this was enhanced in patients who were followed for at least 3 years and those who had an LDL-C (low-density lipoprotein cholesterol) of 100 mg/dL or higher at baseline. Moreover, additional new analyses showed an association between reduced non-fatal cardiovascular (CV) events and reduction in non-CV death during the trial period.

 

Princeton-based BioNJ Member Advaxis, Inc.  announced that it will be continuing its ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac (AXAL) in high-risk, locally advanced cervical cancer (AIM2CERV). The current trial design has a planned sample size of 450 subjects to maintain adequate statistical power over a broader range of survival outcomes, as well as a pre-planned interim analysis (IA) of safety and efficacy. 

 

BioNJ Members   Bristol-Myers Squibb and Pfizer Inc. presented new real-world evidence (RWE) from a sub-analysis of the ARISTOPHANES study comparing the safety and effectiveness of non-vitamin K antagonist oral anticoagulants (NOACs), including Eliquis® (apixaban), in non-valvular atrial fibrillation (NVAF) patient populations aged 80 and older (n=46,208). In the analysis, apixaban use was associated with lower rates of both stroke/systemic embolism (S/SE) and major bleeding (MB) compared to dabigatran ([S/SE hazard ratio (HR): 0.65, 95% confidence interval (CI): 0.47-0.89]; [MB HR: 0.60, 95% CI: 0.49-0.73]) or rivaroxaban ([S/SE HR: 0.72, 95% CI: 0.59-0.86]; [MB HR: 0.50, 95% CI: 0.45-0.55]).

 

Princeton-based BioNJ Member   Bristol-Myers Squibb Company  announced that the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. In ELOQUENT-3, a randomized, open-label, Phase 2 trial, EPd demonstrated benefit in patients with relapsed or refractory multiple myeloma, doubling both median progression-free survival (PFS) and overall response rate (ORR) versus pomalidomide and dexamethasone (Pd).

 

Princeton-based BioNJ Member   Bristol-Myers Squibb Company  and Infinity Pharmaceuticals, Inc. announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's Opdivo in combination with Infinity's IPI-549 in patients with advanced urothelial cancer. IPI-549 is an oral immuno-oncology development candidate that is designed to selectively inhibit phosphoinositide-3-kinase (PI3K)-gamma and is the only investigational PI3K-gamma inhibitor in clinical development.

 

Bridgewater-based BioNJ Member  Eli Lilly and Company  announced the submission of a New Drug Application (NDA) to the  U.S. Food and Drug Administration  ( FDA ) for lasmiditan for the acute treatment of migraine with or without aura in adults. Lasmiditan is an investigational, oral, centrally-penetrant, selective serotonin 5-HT1F agonist that is structurally and mechanistically distinct from other approved migraine therapies and lacks vasoconstrictive activity. It is the first and only molecule in the "-ditan" class under evaluation for the acute treatment of migraine in adults. 

 

Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study showed Bridgewater-based BioNJ Member  Eli Lilly's  Jardiance® was associated with a 44 percent relative risk reduction in hospitalization for heart failure (HHF) compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in routine clinical practice in the U.S. The EMPRISE analysis of data from approximately 35,000 people with type 2 diabetes between August 2014 and September 2016 will be presented at the American Heart Association® (AHA) Scientific Sessions 2018 in Chicago.

Summit-based BioNJ Member Celgene is a company built on a foundation of bold innovation to address areas of significant need for patients with cancer and other debilitating diseases. This unyielding drive has led the company to developments that have transformed the care of diseases like multiple myeloma and pancreatic cancer and has provided important new options for patients with psoriatic diseases.

Summit-based BioNJ Member Celgene has long maintained a dual focus on not only the patients that its therapies treat but the employees at Celgene that work to develop those therapies and get them to market.  Celgene was ranked #9 on the Forbes' World's Best Employers 2018 list.  This year Forbes also gave Celgene placements on the 2018 Global Growth Champions list and America's Best Midsize Employers 2018.

Kenilworth-based BioNJ Member  Merck & Co.  announced that the Phase 3 KEYNOTE-181 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy in the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma has met a primary endpoint of overall survival (OS) in patients whose tumors expressed PD-L1 (Combined Positive Score [CPS] ≥10). In this pivotal study, treatment with KEYTRUDA resulted in a statistically significant improvement in OS compared to chemotherapy (paclitaxel, docetaxel or irinotecan) in patients with CPS ≥10, regardless of histology. 

Kenilworth-based BioNJ Member  Merck & Co.  announced that it has started the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated), the company's investigational vaccine for Ebola Zaire disease. This rolling submission is made pursuant to the FDA's Breakthrough Therapy Designation for V920, which was announced by the company in July 2016.

Kenilworth-based BioNJ Member  Merck & Co. and AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Priority Review for the use of Lynparza  (olaparib) tablets as a maintenance treatment in patients with newly-diagnosed,BRCA -mutated (BRCA m) advanced ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy. A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2019.

Kenilworth-based BioNJ Member  Merck & Co. announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Kenilworth-based BioNJ Member  Merck & Co. announced the first presentations of preliminary safety and efficacy data from Phase 1/2 dose finding studies for the company's investigational anti-LAG-3 therapy (MK-4280) and anti-TIGIT therapy (MK-7684) in patients with advanced solid tumors. LAG-3 and TIGIT are negative immune regulators and play different roles in downregulating the immune response. The preliminary findings from the studies demonstrated acceptable safety profiles with no dose limiting toxicities and early signals of anti-tumor activity for Merck's anti-LAG-3 therapy (MK-4280) (Abstract #O26) and anti-TIGIT therapy (MK-7684) (Abstract #O25) as monotherapies and in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy.

 

Woodcliff Lake-based Eisai Co., and Kenilworth-based BioNJ Member Merck & Co., Inc., announced results from presentations of new data and analyses of LENVIMA®
(lenvatinib), an orally available kinase inhibitor discovered by Eisai, in combination with Merck & Co.'s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in three different tumor types - metastatic non-small cell lung cancer (NSCLC), metastatic melanoma and metastatic urothelial carcinoma.

 

Florham Park-based Cellectar Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted an exemption to the Import Alert placed on the Centre for Probe Development and Commercialization (CPDC), the sole supplier of the CLR 131. The exemption for CLR 131 is effective immediately for all hematology studies and, in response, Cellectar is preparing to dose patients in the second fractionated dose cohort of the Phase 1 relapsed refractory (R/R) multiple myeloma study and the Phase 2 study for R/R hematologic malignancies.

Warren-based Aquestive Therapeutics Inc.  received full approval from the  U.S. Food and Drug Administration  for Sympazan (clobazam) oral film formulation, making it the first oral film approved for the treatment of seizures associated with Lennox-Gastaut syndrome patients 2 years of age or older. LGS is a rare and often debilitating form of childhood-onset epilepsy. Treating LGS can be difficult as some patients may have a hard time swallowing medication and may struggle with complex regimens. Sympazan is a small, thin film strip that is placed on the tongue where it dissolves.

 

Oldwick-based Provention Bio, Inc. and  Amgen announced a licensing and co-development agreement for AMG 714, identified by Provention as PRV-015. AMG 714 is a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease (NRCD). Development efforts at Provention will be led by researchers with previous experience developing AMG 714.

Basking Ridge-based Daiichi Sankyo announced that the European Medicines Agency (EMA) validated for review and granted accelerated assessment to the Marketing Authorization Application (MAA) for quizartinib for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) which is FLT3-ITD positive. Validation confirms that the application is complete and commences the scientific review process by the EMA's Committee for Medicinal Products for Human Use (CHMP).

GlaxoSmithKline plc, with offices in Warren, and Innoviva, Inc. announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI'), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA).  

Eatontown-based Hikma Pharmaceuticals PLC announced that it has signed an agreement with Vectura Group plc (Vectura) for the global development and commercialization of generic versions of GSK's Ellipta® portfolio, utilizing Vectura's proprietary Open-Inhale-Close dry powder inhaler device. Siggi Olafsson, Chief Executive Officer of Hikma, said, "This agreement leverages the investment we have made and the experience we have gained through our generic Advair Diskus® program. By strengthening and expanding our partnership with Vectura, we will develop a pipeline of complex respiratory products that will enable us to deliver sustainable long-term growth."

Takeda Pharmaceutical Company Limited, with offices in East Windsor,  announced the launch of Entyvio®  (generic name: vedolizumab, development code: MLN0002) for the treatment of patients with moderately to severely active ulcerative colitis (UC) in Japan. Takeda submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2017 based on the results from Study CCT-101, a Phase 3 clinical study including 292 Japanese patients with moderately to severely active UC alongside data from the global GEMINI 1 pivotal Phase 3 clinical study of vedolizumab induction and maintenance treatment involving 895 patients with moderately to severely UC.

A ribbon cutting marks the opening of California-based Cryoport's East Coast venture.  Jerrell Shelton, President and CEO of Cryoport,  says he looked at several locations east of the Mississippi River and decided Livingston was ideal because of the growing biomedical industry in New Jersey.  "You have the interstate system here, we've got a friendly community, we're almost in the center of the biologic activity, the pharmaceutical activity. You've got Novartis and Celgene almost equidistant from us, and then we have all those other clients around us here," Shelton said. "It made total sense."

There are a number of companies now attracting attention for coming up with virtual reality, or VR, solutions for clinical settings. And among those trailblazers is a 36-year-old Hasbrouck Heights company that started with a business that was anything but technological.   MediSolutions , led by Erez Lapsker, now has a vision for getting people to better understand what's going on in their bodies by putting them inside. The storied company is developing a platform, MediVRx, that immerses patients in a VR learning experience that involves traveling through skin, bones and arteries.  

Germany-based  Grünenthal has extended its commercial footprint in the United States with its acquisition of Morristown-based  Averitas Pharma.  Under the deal, Averitas will commercialize the pain patch Qutenza for Grünenthal in the U.S. Grünenthal said it has only recently acquired the remaining global rights for the product from Acorda Therapeutics.

 

Pennington-based BioNJ Member  OncoSec Medical Incorporated 

announced the appointment of Robert Ward to its Board of Directors. Mr. Ward is currently Chairman and Chief Executive Officer of Eloxx Pharmaceuticals. 

"It is with great pleasure that we welcome Bob to our Board. His considerable industry experience leading pharmaceutical companies in bringing new therapies to market and deep insight into successful commercialization strategies will be extremely valuable to OncoSec as we continue to advance our TAVO™ platform," said Avtar Dhillon, Chairman of OncoSec.

 

Newark-based BioNJ Member   Rafael Pharmaceuticals, Inc. announced the appointment of Mike Stelmah as Vice President, Manufacturing and Chemistry, Manufacturing and Controls (CMC) Regulatory Affairs, and Jehan Rowlands, PharmD as Vice President of Regulatory Affairs. Dr. Stelmah has extensive pharmaceutical industry experience in CMC and regulatory strategies. 

 

Rutherford-based BioNJ Member Cancer Genetics has appointed Glenn Miles its new Chief Financial Officer. Mr. Miles , who has more than 30 years of experience in accounting and finance, has been a contractor for Cancer Genetics since July of this year.  Before that, he was president and Chief Financial Officer of Catalytic Consulting LLC. Previously, he was a biopharmaceutical controller for Europe, Latin America and U.S. oncology at Pfizer. Prior to Pfizer, he held various senior-level finance roles at Lehman Brothers and AT&T Mobility. He began his career at Grant Thornton.

 

The Institute for Life Science Entrepreneurship at  Kean University was awarded a $100,000 planning grant with Union Township to expand its outreach to life sciences entrepreneurs and its university programs. T he university said that a Union Township proposal to expand ILSE, located in Kean's STEM Building, received one of nine  New Jersey Economic Development Authority  Innovation Challenge awards. The ILSE incubator is a facility that supports eight startup life sciences businesses by providing physical space, shared equipment and support and consultation on the challenging issues facing entrepreneurs.

 

Tumors require nutrients to grow and survive, thus therapeutic approaches to cut off the tumor food supply are important for treating cancer. Autophagy, a normal cellular process in which intracellular components are recycled to provide nutrients to sustain survival during times of stress, is known to facilitate tumor growth, survival, and malignancy. Research from investigators at Rutgers Cancer Institute of New Jersey shows that autophagy in normal tissues as well as the tumor cells themselves also promotes tumor growth. 

 

Rutgers Cancer Institute of New Jersey, in partnership with Robert Wood Johnson University Hospital (RWJUH) - New Brunswick, is the first in the State to administer a form of targeted cancer treatment known as peptide receptor radionuclide therapy (PRRT) for rare neuroendocrine tumors that have spread beyond the initial tumor site. The first patient received treatment October 24 at RWJUH, an RWJBarnabas Health facility in New Brunswick.

 

According to the National Cancer Institute, adolescents and young adults (ages 15 to 39) account for about five percent of all cancer diagnoses in the United States. This is about six times the number of cancers diagnosed in children (ages 0 to 14). Clinical trial access is important for this population, but challenges often exist. To help address these concerns, Rutgers Cancer Institute of New Jersey will utilize a $50,000 infrastructure grant from the St. Baldrick's Foundation to provide additional support for a clinical research nurse dedicated to the needs of adolescents and young adults.

 

Rutgers Cancer Institute of New Jersey researcher 'Jessie' Yanxiang Guo, Ph.D., has received a $150,000 grant from the Lung Cancer Research Foundation (LCRF) to investigate the role of a cell survival mechanism known as autophagy in the development of lung cancers driven by mutations in tumor suppressors known as LKB1 and oncogene KRAS. The aim is to provide new therapeutic approaches to treating non-small cell lung cancer, a sub-type of lung cancer that is active of KRAS and deficient of the LKB1 gene.

 

A number of physicians at Rutgers Cancer Institute of New Jersey -- the State's only National Cancer Institute-designated Comprehensive Cancer Center -- have been recognized by  New Jersey Monthly  magazine as a 'Jersey Choice Top Doctor.'  

Kennedy International Inc. said it recently donated a check for $5,508.26 to the Jacqueline M. Wilentz Comprehensive Breast Center at Monmouth Medical Center. The Center offers services including genetic testing, 3-D breast imaging, mammograms and breast MRIs. It also has breast and reconstructive surgeons, medical and radiation oncologists, radiologists and pathologists on-site at satellite locations in Colts Neck and Howell.

The New Jersey Economic Development Authority (NJEDA) has announced the approval of a record-breaking 61 applications through the State's Angel Investor Tax Credit Program during the third quarter of 2018. The approvals represent the infusion of nearly $21 million in private capital into 13 technology and life sciences companies throughout the Garden State. This uptick in activity highlights momentum generated by Governor Phil Murphy's focus on re-establishing New Jersey as the State of Innovation.

The New Jersey Economic Development Authority (NJEDA) kicked off a series of meetings to begin working with the nine municipalities and counties that were awarded funding through the pilot round of the Innovation Challenge. The meetings come as the NJEDA prepares to begin accepting applications for additional planning projects to be funded through a second round of the Innovation Challenge later this month.

5th Annual Sugar Soiree

November 17, 2018 | Scarsdale, NY

Congenital Hyperinsulinism International (CHI) will be holding its annual Sugar Soiree, on November 17, 2018 at the F enway Golf Club in Scarsdale, NY. CHI, a 501(c)3, is a lifeline to those born with congenital hyperinsulinism (HI) and their families. CHI is the global organization dedicated to supporting children and adults born with HI. CHI also supports research leading to better treatments and a cure and works to raise awareness of the condition to reduce brain damage and death from prolonged hypoglycemia

NJ Office of the Secretary of Higher Education Forums

November 19-20, 2018 | Glassboro & Newark

The Office of the Secretary of Higher Education invites you to a series of forums on the state of higher education in New Jersey.

• Forum on College Access and Affordability; Monday, November 19, 2018 from 3 p.m. - 6 p.m. at Rowan University in the Chamberlain Student Center Ballroom (201 Mullica Hill Road, Glassboro, NJ 08028)
• Forum on Promoting Student Success in Higher Education; Tuesday, November 20, 2018 from 3 p.m. - 6 p.m. at Rutgers University - Newark, in the Essex Room in the Paul Robeson Campus Center (350 Dr. Martin Luther King Jr. Blvd., Newark, NJ 07102

The New England Venture Summit

December 12, 2018 | Boston